Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05814757 · ClinicalTrials.gov registry record · Phase 2
OTX-DED for the Short-term Treatment of the Symptoms of Dry Eye Disease (DED)
A Phase 2 study, sponsored by Ocular Therapeutix.
- Completed
- Registry status
- Phase 2
- Development phase
- 100
- Enrollment target
NCT05814757 is a Phase 2 study that has completed, run by Ocular Therapeutix. The registered enrollment target is 100 participants.
The verdict
NCT05814757, a Phase 2 study, has completed, sponsored by Ocular Therapeutix.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 100 participants
- Enrollment target
Study Summary
To assess the efficacy and safety of OTX-DED for the short-term treatment of the symptoms of DED
Interventions
- DRUG OTX-DED
- DRUG Controlled Insertion
- DRUG Collagen Punctal Plug
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2023-05-11 |
| Est. Completion | 2024-05-22 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05814757
The ClinicalTrials.gov registry entry for NCT05814757 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ocular Therapeutix, which has 20 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which OTX-DED is the first listed.
NCT05814757 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05814757 about?
NCT05814757 is a clinical study titled "OTX-DED for the Short-term Treatment of the Symptoms of Dry Eye Disease (DED)". To assess the efficacy and safety of OTX-DED for the short-term treatment of the symptoms of DED
What is the current status of trial NCT05814757?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 100 participants. The study started on 2023-05-11. Estimated completion is 2024-05-22.
What interventions are being tested in trial NCT05814757?
The interventions under investigation include: OTX-DED (DRUG), Controlled Insertion (DRUG), Collagen Punctal Plug (DRUG).
Who is sponsoring clinical trial NCT05814757?
This trial is sponsored by Ocular Therapeutix, which has 20 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.